Table 2 |
||||
|
Baseline patient characteristics. |
||||
|
Panel A |
Panel B |
|||
|
|
||||
|
Prednisone 15 mg Number = 8 |
Placebo Number = 10 |
Prednisone 7.5 mg Number = 18 |
Placebo Number = 9 |
|
|
|
||||
|
Gender, number (%) |
||||
|
Female |
6 (75.0) |
5 (50.0) |
12 (66.7) |
6 (66.7) |
|
Male |
2 (25.0) |
5 (50.0) |
6 (33.3) |
3 (33.3) |
|
Age, years |
||||
|
Mean (SD) |
61.6 (6.5) |
58.4 (12.8) |
57.9 (13.3) |
55.1 (12.8) |
|
Range |
48 to 69 |
45 to 86 |
37 to 81 |
32 to 71 |
|
Race, number (%) |
||||
|
Asian |
0 (0.0) |
3 (30.0) |
2 (11.1) |
3 (33.3) |
|
Black |
0 (0.0) |
1 (10.0) |
4 (22.1) |
0 (0.0) |
|
White |
8 (100.0) |
6 (60.0) |
12 (66.7) |
6 (66.7) |
|
10MCP Trans PDA, mean (SD) |
9.48 (6.44) |
10.55 (9.54) |
8.31 (8.66) |
9.78 (7.28) |
|
DAS28(CRP), mean (SD) |
5.2 (1.3) |
5.5 (1.6) |
5.3 (1.2) |
5.6 (1.8) |
|
Number of tender joints, mean (SD) |
10.9 (7.4) |
13 (10.1) |
13.6 (8.6) |
18.4 (10.1) |
|
Number of swollen joints, mean (SD) |
10.1 (5.4) |
12.5 (8.7) |
11.3 (5.6) |
16.3 (8.6) |
|
CRP (mg/L), median (quartiles) |
8.4 (4.2-25.3) |
14.0 (3.5-37.2) |
6.9 (1.7-14.6) |
3.7 (0.7 - 11.4) |
|
Patients with positive rheumatoid factora, number (%) |
6 (75.0) |
6 (60.0) |
16 (88.9) |
6 (66.7) |
|
|
||||
|
In this instance, the 10MCP Trans PDA for Panel A used data from all three baseline scans. There were no statistically significant differences, P >0.05, between groups based on nonparametric Wilcoxon and t-tests. aPositive rheumatoid factor was defined as rheumatoid factor >= 12 KU/L, the reference range for Quest assay. CRP, C-reactive protein; DAS28, Disease Activity Score in 28 Joints; MCP, metacarpophalangeal joint; PDA; Power Doppler Area; SD, standard deviation. |
||||
|
Seymour et al. Arthritis Research & Therapy 2012 14:R198 doi:10.1186/ar4034 |
||||
